Harvard Accounts Payable from 2010 to 2024
| HBIO Stock | USD 2.24 0.03 1.32% |
Accounts Payable | First Reported 2000-09-30 | Previous Quarter 5.7 M | Current Value 5.3 M | Quarterly Volatility 1.8 M |
Check Harvard Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Harvard Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 M, Interest Expense of 3.8 M or Total Revenue of 96.8 M, as well as many indicators such as Price To Sales Ratio of 1.72, Dividend Yield of 0.0022 or PTB Ratio of 4.65. Harvard financial statements analysis is a perfect complement when working with Harvard Bioscience Valuation or Volatility modules.
Harvard | Accounts Payable |
Latest Harvard Bioscience's Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Harvard Bioscience over the last few years. An accounting item on the balance sheet that represents Harvard Bioscience obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Harvard Bioscience are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Harvard Bioscience's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Harvard Bioscience's overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Harvard Accounts Payable Regression Statistics
| Arithmetic Mean | 5,613,353 | |
| Geometric Mean | 5,372,096 | |
| Coefficient Of Variation | 26.70 | |
| Mean Deviation | 999,678 | |
| Median | 5,554,000 | |
| Standard Deviation | 1,498,786 | |
| Sample Variance | 2.2T | |
| Range | 6.9M | |
| R-Value | 0.36 | |
| Mean Square Error | 2.1T | |
| R-Squared | 0.13 | |
| Significance | 0.19 | |
| Slope | 120,206 | |
| Total Sum of Squares | 31.4T |
Harvard Accounts Payable History
About Harvard Bioscience Financial Statements
Harvard Bioscience investors utilize fundamental indicators, such as Accounts Payable, to predict how Harvard Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 5.6 M | 5.7 M |
Check out the analysis of Harvard Bioscience Correlation against competitors. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share 2.258 | Quarterly Revenue Growth (0.13) | Return On Assets (0.02) |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.